|
AstraZeneca, Rigel Sign Potentially $100M Asthma Drug Deal
Genetic Engineering News Drug firm will start first-in-man studies and carry out clinical development program for R256. |
View full post on asthma – Google News
Rigel, AstraZeneca strike potential $100M asthma drug deal – Bizjournals.com (blog)
|
Rigel, AstraZeneca strike potential $100M asthma drug deal
Bizjournals.com (blog) AstraZeneca will license an experimental asthma treatment from South San Francisco's… |
View full post on asthma – Google News
AstraZeneca and Rigel strike asthma deal worth up to $100M – FierceBiotech
|
AstraZeneca and Rigel strike asthma deal worth up to $100M
FierceBiotech The deal hinges on Rigel's candidate known as R256, an inhalable JAK inhibitor under evaluation for treating tough cases of asthma. AstraZeneca And Rigel Sign Worldwide License Agreement For A … AstraZeneca, Rigel to Develop Asthma Treatment Rigel, AstraZeneca strike potential $100M asthma drug deal |
View full post on asthma – Google News
No Asthma Improvement For Decade Has Cost NHS 100m Pounds – Asthma UK Scotland – Medical News Today (press release)
|
No Asthma Improvement For Decade Has Cost NHS 100m Pounds – Asthma UK Scotland
Medical News Today (press release) The number of people being rushed to hospital because of their asthma is the same as it was in 2000 – and at an annual cost of £10m, Asthma UK Scotland has … |
View full post on asthma – Google News